Regeneron Pharmaceuticals Inc $ 574.06 16.6 (2.98%)

Volume:
639,883
Avg Vol (1m):
686,337
Market Cap $:
61.08 Bil
Enterprise Value $:
60.15 Bil
P/E (TTM):
22.22
P/B:
6.73
Warning! GuruFocus has detected 1 Severe warning sign with REGN. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Regeneron Pharmaceuticals Inc () from 1991 to Sep 25 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Regeneron Pharmaceuticals stock (REGN) PE ratio as of Sep 25 2020 is 22.22. More Details

Regeneron Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Regeneron Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1301
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Regeneron Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-09-2622.2 2020-07-2724.7
2020-09-2522.2 2020-07-2423.6
2020-09-2421.6 2020-07-2324.4
2020-09-2321.9 2020-07-2224.7
2020-09-2222.1 2020-07-2124.7
2020-09-2121.5 2020-07-2025.5
2020-09-1821.5 2020-07-1724.9
2020-09-1721.9 2020-07-1624.5
2020-09-1622.0 2020-07-1524.5
2020-09-1522.5 2020-07-1424.8
2020-09-1421.8 2020-07-1323.8
2020-09-1121.1 2020-07-1024.0
2020-09-1021.3 2020-07-0924.8
2020-09-0922.1 2020-07-0824.8
2020-09-0821.8 2020-07-0724.8
2020-09-0722.5 2020-07-0624.3
2020-09-0422.5 2020-07-0324.1
2020-09-0322.4 2020-07-0224.1
2020-09-0223.6 2020-07-0123.6
2020-09-0123.0 2020-06-3024.1
2020-08-3124.0 2020-06-2923.7
2020-08-2823.3 2020-06-2630.7
2020-08-2723.8 2020-06-2531.2
2020-08-2623.7 2020-06-2430.4
2020-08-2523.6 2020-06-2331.6
2020-08-2423.0 2020-06-2231.6
2020-08-2123.4 2020-06-1932.4
2020-08-2023.9 2020-06-1830.0
2020-08-1924.4 2020-06-1730.3
2020-08-1824.0 2020-06-1629.8
2020-08-1724.0 2020-06-1529.7
2020-08-1423.7 2020-06-1229.6
2020-08-1323.7 2020-06-1130.0
2020-08-1223.7 2020-06-1030.5
2020-08-1123.2 2020-06-0930.6
2020-08-1023.6 2020-06-0830.4
2020-08-0724.0 2020-06-0530.0
2020-08-0624.1 2020-06-0430.1
2020-08-0524.2 2020-06-0330.4
2020-08-0425.1 2020-06-0231.0
2020-08-0325.0 2020-06-0130.1
2020-07-3124.5 2020-05-2930.8
2020-07-3024.5 2020-05-2829.1
2020-07-2924.5 2020-05-2727.3
2020-07-2824.4 2020-05-2627.4

Regeneron Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.